Therapeutic Uses
Anti-Cancer / Oncology
Storage Condition
Store at refrigerator (2-8°C) for long term storage
Synonyms
N-[2-Diethylamino(ethyl-d4)]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
Application Notes
Useful research chemical for a range of applications
Purity by HPLC
Not less than 90%
Hazard Compound
No -Refer MSDS for accurate information
Sunitinib-d4 is a drug product that is used as an analytical standard for HPLC, as well as in research and development of drugs.
Refund Policy
We are committed to offering products of the highest quality in order to meet the needs of our customers, and have elaborate systems in
place to ensure that material specifications, their certification and all handling and storage conditions are communicated at the time of
material handover.
We have invested in the highest quality packaging materials and use international logistics partners to service our customers. While all
possible precautions have been taken to deliver the required product(s), there may be some rare situations when our product does not
meet your requirements. Should that arise, please contact us with your concerns and we will endeavour to address them on a priority
basis. If there is no other option, we will either replace your product(s) or issue a refund or account credit, whichever you prefer.
If there is an issue with one or more of our products, our policy is that it must be reported to us within 45 days of your receiving shipment.
While we will always address product issues after the 45 day return window has passed, we cannot issue a refund or account credit. As
always, we appreciate your support.
Sunitinib-d4 usage and description
Sunitinib D4 is a deuterated form of Sunitinib, a small molecule drug that functions as a multi-targeted receptor tyrosine kinase inhibitor. It is used in the treatment of advanced renal cell carcinoma, gastrointestinal stromal tumors, and pancreatic neuroendocrine tumors. Sunitinib D4 is an isotopically labeled form of the drug, containing a higher percentage of deuterium atoms than the non-deuterated form.
The chemical structure of Sunitinib D4 is C22H17D4ClN4O, and its molecular weight is 406.9 g/mol. It is a yellow to orange powder that is slightly soluble in water. The deuterium atoms in Sunitinib D4 serve to increase its stability and decrease its metabolism rate, resulting in a longer half-life and improved pharmacokinetic properties compared to the non-deuterated form.
Sunitinib D4 works by inhibiting the activity of various receptor tyrosine kinases, such as vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor receptors (PDGFR), and stem cell factor receptor (KIT). By inhibiting these receptors, Sunitinib D4 blocks the growth and division of cancer cells, as well as preventing the formation of new blood vessels that tumors rely on for nutrients and oxygen.
In conclusion, Sunitinib D4 is an important drug used in the treatment of several types of cancer. Its deuterated form provides improved pharmacokinetic properties and stability, allowing for more effective treatment outcomes.
